作者@article {Hulstaert1555 = {F。Hulstaert a和k . Blennow Ivanoiu H.C. Schoonderwaldt和m . Riemenschneider P.P. De走和c . Bancher p .耐腐蚀合金和j . Wiltfang下梅塔和k Iqbal h . Pottel和大肠Vanmechelen h Vanderstichele}, title ={改善歧视广告的病人使用β-amyloid(1-42)和τ水平CSF},体积={52}={8},页面= {1555 - 1555}= {1999},doi = {10.1212 / WNL.52.8.1555},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:探讨脑脊液β-amyloid水平(1-42)(Aβ42)单独和结合脑脊液τ区分广告和其他条件。首页方法:在10中心在欧洲和美国,150 AD患者的脑脊液样本分析,与100年相比健康志愿者的脑脊液样本或患者大脑的疾病与病理条件无关(CON), 84名患者与其他神经疾病(ND),和79年non-Alzheimer类型的痴呆患者(NAD)。夹心ELISA技术现场用于测量Aβ42和τ。结果:平均水平的Aβ42 CSF显著降低在广告(487 pg / mL)反对(849 pg / mL;p = 0.001), ND (643 pg / mL;p = 0.001),和NAD (603 pg / mL;p = 0.001)。歧视的广告欺诈和ND显著提高了综合评估Aβ42和τ。85 \ %的敏感性,特异性的结合测试86 \ % (95 \ % CI: 81 \ 91 \ % %)与55 \ % (95 \ % CI: 47 \ % 62 \ %) Aβ42孤独和65 \ % (95 \ % CI: 58 \ % 72 \ %)为τ。合并后的测试在85 \ %敏感性58 \ % (95 \ % CI: 47 \ % 69 \ %)特定的河畔。 The APOE e4 gene load was negatively correlated with Aβ42 levels not only in AD but also in NAD.Conclusions: The combined measure of CSF Aβ42 and tau meets the requirements for clinical use in discriminating AD from normal aging and specific neurologic disorders.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/52/8/1555}, eprint = {//www.ez-admanager.com/content/52/8/1555.full.pdf}, journal = {Neurology} }